Splendris, a Shenzhen Salubris Pharma affiliate, acquired China rights to a novel MedAlliance cardiovascular balloon by making a $20 million investment in MedAlliance and agreeing to pay up to $10 million in milestones. Selution is a clinical-stage ...

ChinaBio® Daily Update

Contents


Salubris Acquires China Rights to MedAlliance CV Balloon for $30 Million

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Splendris, a Shenzhen Salubris Pharma affiliate, acquired China rights to a novel MedAlliance cardiovascular balloon by making a $20 million investment in MedAlliance and agreeing to pay up to $10 million in milestones. Selution is a clinical-stage sirolimus micro-reservoir drug-coated balloon (DCB). Splendris expects Selution's sirolimus micro-depots balloons will prove to be safer and more effective than paclitaxel-coated balloons, the current standard of care. MedAlliance is located in Switzerland. More details....

Stock Symbol: (SHZ: 2294)

Share this with colleagues:

     
 

Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Deals and Financings 

  • Fosun Pharma is one of the finalists in a $2 billion bidding war for part of Novartis' US portfolio of generic drugs;
  • China Resources Pharma is in talks to pay $613 million for a controlling stake in Jiangzhong Group, a TCM company;  
  • WuXi Biologics will build a $240 million CDMO facility in northern China's Shijiazhuang after announcing a $392 million biologics CDMO facility in Ireland three weeks ago;
  • Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in a $135 million deal;
  • San Diego's Ansun Biopharma closed an $85 million Series A financing round from China investors for anti-viral biologic therapeutics;
  • HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, completed a $37.5 million Series B financing led by two China investors;
  • Changshan Biochemical signed a $9.5 million deal to commercialize an osteoarthritis treatment in China developed by Israel's Kitov Pharma;
  • Jiangsu Ambition in-licensed China rights to a prostate treatment that is delivered via an injected depot system, which administers the drug directly to the tumor;
  • Asymchem Labs (Tianjin) co-founded the Innovative Drug Fund to complete in-licensings and partnerships that bring innovative western drugs to China;

Trials and Approvals 

  • Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, in patients with Hodgkin Lymphoma;
  • Beijing's BeiGene enrolled the first patient in a China Phase III trial of pamiparib, a PARP inhibitor used as a maintenance therapy in ovarian cancer patients;  
  • CStone Pharma of Suzhou dosed the first patient in a Australian Phase I clinical trial of CS1003, a PD-1 candidate aimed at solid tumor cancers;

Government and Regulatory 

  • China plans to increase patent protection on innovative drug to 25 years, up from the current 20 years, an answer to US tariffs on China goods, following US allegations that China does not observe international IP protection standards.

Stock Symbols: (SHA: 600196; HK: 02196) (NYSE: NVS) (HK: 3320) (SHA: 600750) (HK: 2269) (SHA: 600867) (Paris: ADOC) (SHZ: 300255) (NSDQ: KTOV) (SHZ: 002821) (NSDQ: BGNE)

Share this with colleagues:

     
 

CR Pharma in Talks for $613 Million Acquisition of Jiangzhong Pharma

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

China Resources Pharmaceutical Group is in talks to pay $613 million for a controlling stake in Jiangzhong Group, the country’s fifth largest maker of traditional Chinese medicines. Jiangzhong, which is 42% owned by the Jiangxi provincial government, owns a 43% stake in Shanghai-listed Jiangzhong Pharma, a company with a market capitalization of $1.2 billion. Both CR Pharma and Jiangzhong are State-Owned enterprises, and the transaction, if completed, would help to consolidate/reform China's network of state-owned drugmakers. More details....

Stock Symbols: (HK: 3320) (SHA: 600750)

Share this with colleagues:

     
 

BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

BeiGene, a Beijing oncology company, has enrolled the first patient in a China Phase III trial of pamiparib (BGB-290), a PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. The drug will be administered as a maintenance therapy in patients whose ovarian cancer has recurred. Pamiparib is also being tested as a monotherapy and in combination regimens for a variety of solid tumor malignancies. BeiGene pointed out that, to date, there are no PARP inhibitors approved for China use. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:

     
 

WuXi Biologics Plans Another New CDMO Plant -- A $240 Million Facility in Shijiazhuang

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

WuXi Biologics will build a $240 million CDMO facility in Shijiazhuang, the capital of China's northern Hebei province. The new facility is an addition to WuXi Biologics' existing CDMO facilities in Shanghai and a $392 million biologics CDMO facility in Ireland, announced last month. WuXi said the Shijiazhuang facility, which will employ 1,000 people, will be operational in 2020. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy